Dengue: knowledge gaps, unmet needs, and research priorities

The Lancet Infectious Diseases

Volumn 17, Issue 3, 2017, Pages e88-e100

  Katzelnick, Leah C ^a   Coloma, Josefina ^a   Harris, Eva ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE VACCINE; NEUTRALIZING ANTIBODY;

ANTIBODY DEPENDENT ENHANCEMENT; B LYMPHOCYTE; CASE MANAGEMENT; CLINICAL FEATURE; CLINICAL RESEARCH; DENGUE; DENGUE VIRUS; DIAGNOSTIC PROCEDURE; DISEASE SURVEILLANCE; DISEASE TRANSMISSION; EPIDEMIC; GENOTYPE; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; LOWEST INCOME GROUP; MIDDLE INCOME COUNTRY; POST PRIMARY INFECTION; PREVENTION AND CONTROL; PRIORITY JOURNAL; PROGNOSIS; REINFECTION; RESEARCH PRIORITY; REVIEW; SECONDARY INFECTION; SEROEPIDEMIOLOGY; SEROTYPE; T LYMPHOCYTE; VECTOR CONTROL; VIRUS PATHOGENESIS; VIRUS STRAIN; ANIMAL; IMMUNOLOGY; INSECT VECTOR; PUBLIC HEALTH; RESEARCH; VIROLOGY;

ANIMALS; DENGUE; DENGUE VACCINES; DENGUE VIRUS; HUMANS; INSECT VECTORS; PUBLIC HEALTH; RESEARCH;

EID: 85011579533     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(16)30473-X     Document Type: Review

References (150)

1. 1 Bhatt, S, Gething, PW, Brady, OJ, et al. The global distribution and burden of dengue. Nature 496 (2013), 504–507.
2. 2 Radke, EG, Gregory, CJ, Kintziger, KW, et al. Dengue outbreak in Key West, Florida, USA, 2009. Emerg Infect Dis 18 (2012), 135–137.
3. 3 Schaffner, F, Mathis, A, Dengue and dengue vectors in the WHO European region: past, present, and scenarios for the future. Lancet Infect Dis 14 (2014), 1271–1280.
4. 4 WHO. Global strategy for dengue prevention and control, 2012, World Health Organization, Geneva.
5. 5 Shepard, DS, Undurraga, EA, Betancourt-Cravioto, M, et al. Approaches to refining estimates of global burden and economics of dengue. PLoS Negl Trop Dis, 8, 2014, e3306.
6. 6 GBD 2015 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388 (2016), 1603–1658.
7. 7 WHO. Dengue haemorrhagic fever: diagnosis, treatment, prevention and control, 2nd edn., 1997, World Health Organization, Geneva.
8. 8 WHO and TDR. Dengue: guidelines for diagnosis, treatment, prevention and control, 2009, World Health Organization, Geneva.
9. 9 Teoh, BT, Sam, SS, Tan, KK, et al. Early detection of dengue virus by use of reverse transcription-recombinase polymerase amplification. J Clin Microbiol 53 (2015), 830–837.
10. 10 Hunsperger, EA, Yoksan, S, Buchy, P, et al. Evaluation of commercially available diagnostic tests for the detection of dengue virus NS1 antigen and anti-dengue virus IgM antibody. PLoS Negl Trop Dis, 8, 2014, e3171.
11. 11 John, DV, Lin, Y-S, Perng, GC, Biomarkers of severe dengue disease—a review. J Biomed Sci, 22, 2015, 83.
12. 12 Wesolowski, A, Qureshi, T, Boni, MF, et al. Impact of human mobility on the emergence of dengue epidemics in Pakistan. Proc Natl Acad Sci USA 112 (2015), 11887–11892.
13. 13 Lozano-Fuentes, S, Wedyan, F, Hernandez-Garcia, E, et al. Cell phone-based system (Chaak) for surveillance of immatures of dengue virus mosquito vectors. J Med Entomol 50 (2013), 879–889.
14. 14 Morrison, AC, Minnick, SL, Rocha, C, et al. Epidemiology of dengue virus in Iquitos, Peru 1999 to 2005: interepidemic and epidemic patterns of transmission. PLoS Negl Trop Dis, 4, 2010, e670.
15. 15 Montoya, M, Gresh, L, Mercado, JC, et al. Symptomatic versus inapparent outcome in repeat dengue virus infections is influenced by the time interval between infections and study year. PLoS Negl Trop Dis, 7, 2013, e2357.
16. 16 Achee, NL, Gould, F, Perkins, TA, et al. A critical assessment of vector control for dengue prevention. PLoS Negl Trop Dis, 9, 2015, e0003655.
17. 17 PAHO. State of the art in the prevention and control of dengue in the Americas, 2014, Pan American Health Organization, Washington, DC.
18. 18 Gubler, DJ, The partnership for dengue control—a new global alliance for the prevention and control of dengue. Vaccine, 33, 2015, 1233.
19. 19 Andersson, N, Nava-Aguilera, E, Arosteguí, J, et al. Evidence based community mobilization for dengue prevention in Nicaragua and Mexico (Camino Verde, the Green Way): cluster randomized controlled trial. BMJ, 351, 2015, h3267.
20. 20 George, L, Lenhart, A, Toledo, J, et al. Community-effectiveness of temephos for dengue vector control: a systematic literature review. PLoS Negl Trop Dis, 9, 2015, e0004006.
21. 21 Hurst, TP, Kay, BH, Brown, MD, Ryan, PA, Melanotaenia duboulayi influence oviposition site selection by Culex annulirostris (Diptera: Culicidae) and Aedes notoscriptus (Diptera: Culicidae) but not Culex quinquefasciatus (Diptera: Culicidae). Environ Entomol 39 (2010), 545–551.
22. 22 Winskill, P, Carvalho, DO, Capurro, ML, Alphey, L, Donnelly, CA, McKemey, AR, Dispersal of engineered male Aedes aegypti mosquitoes. PLoS Negl Trop Dis 9 (2015), 1–18.
23. 23 Hoffmann, AA, Montgomery, BL, Popovici, J, et al. Successful establishment of wolbachia in aedes populations to suppress dengue transmission. Nature 476 (2011), 454–457.
24. 24 Nguyen, TH, Nguyen, H Le, Nguyen, TY, et al. Field evaluation of the establishment potential of wMelPop wolbachia in Australia and Vietnam for dengue control. Parasit Vectors, 8, 2015, 563.
25. 25 Arunachalam, N, Tyagi, BK, Samuel, M, et al. Community-based control of Aedes aegypti by adoption of eco-health methods in Chennai City, India. Pathog Glob Health 106 (2012), 488–496.
26. 26 Ferguson, NM, Kien, DTH, Clapham, H, et al. Modeling the impact on virus transmission of wolbachia-mediated blocking of dengue virus infection of Aedes aegypti. Sci Transl Med, 7, 2015, 279ra37.
27. 27 Reiner, RC, Stoddard, ST, Scott, TW, Socially structured human movement shapes dengue transmission despite the diffusive effect of mosquito dispersal. Epidemics 6 (2014), 30–36.
28. 28 Perkins, TA, Garcia, AJ, Paz-Soldan, VA, et al. Theory and data for simulating fine-scale human movement in an urban environment. J R Soc Interface, 11, 2014, 20140642.
29. 29 Rabaa, MA, Simmons, CP, Fox, A, et al. Dengue virus in sub-tropical northern and central Viet Nam: population immunity and climate shape patterns of viral invasion and maintenance. PLoS Negl Trop Dis, 7, 2013, e2581.
30. 30 van Panhuis, WG, Choisy, M, Xiong, X, et al. Region-wide synchrony and traveling waves of dengue across eight countries in Southeast Asia. Proc Natl Acad Sci 112 (2015), 13069–13074.
31. 31 Cummings, DAT, Iamsirithaworn, S, Lessler, JT, et al. The impact of the demographic transition on dengue in Thailand: insights from a statistical analysis and mathematical modeling. PLoS Med, 6, 2009, e1000139.
32. 32 Rodríguez-Barraquer, I, Buathong, R, Iamsirithaworn, S, et al. Revisiting Rayong: shifting seroprofiles of dengue in Thailand and their implications for transmission and control. Am J Epidemiol 179 (2014), 353–360.
33. 33 Waggoner, JJ, Balmaseda, A, Gresh, L, et al. Homotypic dengue virus reinfections in Nicaraguan children. J Infect Dis 214 (2016), 968–993.
34. 34 Duong, V, Lambrechts, L, Paul, RE, et al. Asymptomatic humans transmit dengue virus to mosquitoes. Proc Natl Acad Sci 112 (2015), 14688–14693.
35. 35 Katzelnick, LC, Montoya, M, Gresh, L, Balmaseda, A, Harris, E, Neutralizing antibody titers against dengue virus correlate with protection from symptomatic infection in a longitudinal cohort. Proc Natl Acad Sci USA 113 (2016), 728–733.
36. 36 Clapham, HE, Rodriguez-Barraquer, I, Azman, AS, et al. Dengue virus (DENV) neutralizing antibody kinetics in children after symptomatic primary and postprimary DENV infection. J Infect Dis 213 (2016), 1428–1435.
37. 37 Fox, A, Whitehead, S, Anders, KL, et al. Investigation of dengue and Japanese encephalitis virus transmission in Hanam, Vietnam. Am J Trop Med Hyg 90 (2014), 892–896.
38. 38 Perkins, TA, Reiner, RC, Rodriguez-Barraquer, I, Smith, DL, Scott, TW, Cummings, DAT, A review of transmission models of dengue: a quantitative and qualitative analysis of model features. Gubler, DJ, Ooi, EE, Vasudevan, SG, Farrar, J, (eds.) Dengue and dengue hemorrhagic fever, 2nd edn., 2014, CAB International, Wallingford, 99–114.
39. 39 Forshey, BM, Reiner, RC, Olkowski, S, et al. Incomplete protection against dengue virus type 2 re-infection in Peru. PLoS Negl Trop Dis, 10, 2016, e0004398.
40. 40 Hadinegoro, SR, Arredondo-García, JL, Capeding, MR, et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med 373 (2015), 1195–1206.
41. 41 Capeding, MR, Tran, NH, Hadinegoro, SR, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 384 (2014), 1358–1365.
42. 42 Villar, L, Dayan, GH, Arredondo-García, JL, et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med 372 (2015), 113–123.
43. 43 Coudeville, L, Baurin, N, Vergu, E, Estimation of parameters related to vaccine efficacy and dengue transmission from two large phase III studies. Vaccine 34 (2015), 6417–6425.
44. 44 Nisalak, A, Endy, TP, Nimmannitya, S, et al. Serotype-specific dengue virus circulation and dengue disease in Bangkok, Thailand from 1973 to 1999. Am J Trop Med Hyg 68 (2003), 191–202.
45. 45 Balmaseda, A, Hammond, SN, Pérez, L, et al. Serotype-specific differences in clinical manifestations of dengue. Am J Trop Med Hyg 74 (2006), 449–456.
46. 46 OhAinle, M, Harris, E, Dengue pathogenesis: viral factors. Gubler, DJ, Ooi, EE, Vasudevan, SG, Farrar, J, (eds.) Dengue and dengue hemorrhagic fever, 2nd edn., 2014, CAB International, Wallingford, 231–250.
47. 47 OhAinle, M, Balmaseda, A, Macalalad, AR, et al. Dynamics of dengue disease severity determined by the interplay between viral genetics and serotype-specific immunity. Sci Transl Med, 3, 2011, 114ra128.
48. 48 Bhoomiboonchoo, P, Nisalak, A, Chansatiporn, N, et al. Sequential dengue virus infections detected in active and passive surveillance programs in Thailand, 1994–2010. BMC Public Health 15 (2015), 1–10.
49. 49 Kochel, TJ, Watts, DM, Halstead, SB, et al. Effect of dengue-1 antibodies on American dengue-2 viral infection and dengue haemorrhagic fever. Lancet 360 (2002), 310–312.
50. 50 Olkowski, S, Forshey, BM, Morrison, AC, et al. Reduced risk of disease during postsecondary dengue virus infections. J Infect Dis 208 (2013), 1026–1033.
51. 51 Guirakhoo, F, Pugachev, K, Arroyo, J, et al. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates. Virology 298 (2002), 146–159.
52. 52 VanBlargan, LA, Mukherjee, S, Dowd, KA, Durbin, AP, Whitehead, SS, Pierson, TC, The type-specific neutralizing antibody response elicited by a dengue vaccine candidate is focused on two amino acids of the envelope protein. PLoS Pathog, 9, 2013, e1003761.
53. 53 Wang, C, Katzelnick, LC, Montoya, M, Hue, KDT, Simmons, CP, Harris, E, Evolutionarily successful asian 1 dengue virus 2 lineages contain one substitution in envelope that increases sensitivity to polyclonal antibody neutralization. J Infect Dis 213 (2016), 975–984.
54. 54 Dowd, KA, DeMaso, CR, Pierson, TC, Genotypic differences in dengue virus neutralization are explained by a single amino acid mutation that modulates virus breathing. MBio 6 (2015), e01559–e01560.
55. 55 Zhang, C, Mammen, MP, Chinnawirotpisan, P, et al. Clade replacements in dengue virus serotypes 1 and 3 are associated with changing serotype prevalence. J Virol 79 (2005), 15123–15130.
56. 56 Quiner, CA, Parameswaran, P, Ciota, AT, et al. Increased replicative fitness of a dengue virus 2 clade in native mosquitoes: potential contribution to a clade replacement event in Nicaragua. J Virol 88 (2014), 13125–13134.
57. 57 Adams, B, Holmes, EC, Zhang, C, et al. Cross-protective immunity can account for the alternating epidemic pattern of dengue virus serotypes circulating in Bangkok. Proc Natl Acad Sci USA 103 (2006), 14234–14239.
58. 58 Bennett, SN, Holmes, EC, Chirivella, M, et al. Molecular evolution of dengue 2 virus in Puerto Rico: positive selection in the viral envelope accompanies clade reintroduction. J Gen Virol 87 (2006), 885–893.
59. 59 Twiddy, SS, Woelk, CH, Holmes, EC, Phylogenetic evidence for adaptive evolution of dengue viruses in nature. J Gen Virol 83 (2002), 1679–1689.
60. 60 Cummings, DAT, Schwartz, IB, Billings, L, Shaw, LB, Burke, DS, Dynamic effects of antibody-dependent enhancement on the fitness of viruses. Proc Natl Acad Sci USA 102 (2005), 15259–15264.
61. 61 Recker, M, Blyuss, KB, Simmons, CP, et al. Immunological serotype interactions and their effect on the epidemiological pattern of dengue. Proc Biol Sci 276 (2009), 2541–2548.
62. 62 Wearing, HJ, Rohani, P, Ecological and immunological determinants of dengue epidemics. Proc Natl Acad Sci USA 103 (2006), 11802–11807.
63. 63 Sabchareon, A, Wallace, D, Sirivichayakul, C, et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 380 (2012), 1559–1567.
64. 64 Durbin, AP, Kirkpatrick, BD, Pierce, KK, et al. A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial. J Infect Dis 207 (2013), 957–965.
65. 65 Anderson, KB, Gibbons, R V, Cummings, DAT, et al. A shorter time interval between first and second dengue infections is associated with protection from clinical illness in a school-based cohort in Thailand. J Infect Dis 209 (2014), 360–368.
66. 66 Reich, NG, Shrestha, S, King, AA, et al. Interactions between serotypes of dengue highlight epidemiological impact of cross-immunity. J R Soc Interface, 10, 2013, 20130414.
67. 67 Weiskopf, D, Sette, A, T-cell immunity to infection with dengue virus in humans. Front Immunol, 5, 2014, 93.
68. 68 Corbett, KS, Katzelnick, L, Tissera, H, Amerasinghe, A, de Silva, AD, de Silva, AM, Preexisting neutralizing antibody responses distinguish clinically inapparent and apparent dengue virus infections in a Sri Lankan pediatric cohort. J Infect Dis 211 (2015), 590–599.
69. 69 Puschnik, A, Lau, L, Cromwell, EA, Balmaseda, A, Zompi, S, Harris, E, Correlation between dengue-specific neutralizing antibodies and serum avidity in primary and secondary dengue virus 3 natural infections in humans. PLoS Negl Trop Dis, 7, 2013, e2274.
70. 70 Halstead, SB, Papaevangelou, G, Transmission of dengue 1 and 2 viruses in Greece in 1928. Am J Trop Med Hyg 29 (1980), 635–637.
71. 71 Guzman, MG, Alvarez, M, Rodriguez-Roche, R, et al. Neutralizing antibodies after infection with dengue 1 virus. Emerg Infect Dis 13 (2007), 282–286.
72. 72 Halstead, SB, Grosz, CR, Subclinical Japanese encephalitis. I. Infection of Americans with limited residence in Korea. Am J Hyg 75 (1962), 190–201.
73. 73 Hickey, AC, Koster, JA, Thalmann, CM, et al. Serotype-specific host responses in rhesus macaques after primary dengue challenge. Am J Trop Med Hyg 89 (2013), 1043–1057.
74. 74 Koraka, P, Benton, S, van Amerongen, G, Stittelaar, KJ, Osterhaus, AD, Characterization of humoral and cellular immune responses in cynomolgus macaques upon primary and subsequent heterologous infections with dengue viruses. Microbes Infect 9 (2007), 940–946.
75. 75 Katzelnick, LC, Fonville, JM, Gromowski, GD, et al. Dengue viruses cluster antigenically but not as discrete serotypes. Science 349 (2015), 1338–1343.
76. 76 Gibbons, RV, Kalanarooj, S, Jarman, RG, et al. Analysis of repeat hospital admissions for dengue to estimate the frequency of third or fourth dengue infections resulting in admissions and dengue hemorrhagic fever, and serotype sequences. Am J Trop Med Hyg 77 (2007), 910–913.
77. 77 Rouvinski, A, Guardado-Calvo, P, Barba-Spaeth, G, et al. Recognition determinants of broadly neutralizing human antibodies against dengue viruses. Nature 520 (2015), 109–113.
78. 78 Sabin, AB, Research on dengue during World War II. Am J Trop Med Hyg 1 (1952), 30–50.
79. 79 Halstead, S, Casals, J, Studies on the immunization of monkeys against dengue I. Protection derived from single and sequential virus infections. Am J Trop Med Hyg 22 (1973), 365–374.
80. 80 Halstead, SB, Identifying protective dengue vaccines: guide to mastering an empirical process. Vaccine 31 (2013), 4501–4507.
81. 81 Bernardo, L, Izquierdo, A, Prado, I, et al. Primary and secondary infections of Macaca fascicularis monkeys with Asian and American genotypes of dengue virus 2. Clin Vaccine Immunol 15 (2008), 439–446.
82. 82 Thomas, SJ, Nisalak, A, Anderson, KB, et al. Dengue plaque reduction neutralization test (PRNT) in primary and secondary dengue virus infections: how alterations in assay conditions impact performance. Am J Trop Med Hyg 81 (2009), 825–833.
83. 83 Mukherjee, S, Dowd, KA, Manhart, CJ, et al. Mechanism and significance of cell type-dependent neutralization of flaviviruses. J Virol 88 (2014), 7210–7220.
84. 84 Pierson, TC, Xu, Q, Nelson, S, et al. The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. Cell Host Microbe 1 (2007), 135–145.
85. 85 Plevka, P, Battisti, AJ, Sheng, J, Rossmann, MG, Mechanism for maturation-related reorganization of flavivirus glycoproteins. J Struct Biol 185 (2014), 27–31.
86. 86 Austin, SK, Dowd, K, Shrestha, B, et al. Structural basis of differential neutralization of DENV-1 genotypes by an antibody that recognizes a cryptic epitope. PLoS Pathog, 8, 2012, e1002930.
87. 87 Brien, JD, Austin, SK, Sukupolvi-Petty, S, et al. Genotype-specific neutralization and protection by antibodies against dengue virus type 3. J Virol 84 (2010), 10630–10643.
88. 88 Timiryasova, TM, Bonaparte, MI, Luo, P, Zedar, R, Hu, BT, Hildreth, SW, Optimization and validation of a plaque reduction neutralization test for the detection of neutralizing antibodies to four serotypes of dengue virus used in support of dengue vaccine development. Am J Trop Med Hyg 88 (2013), 962–970.
89. 89 Endy, TP, Nisalak, A, Chunsuttitwat, S, et al. Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. J Infect Dis 189 (2004), 990–1000.
90. 90 Buddhari, D, Aldstadt, J, Endy, TP, et al. Dengue virus neutralizing antibody levels associated with protection from infection in Thai cluster studies. PLoS Negl Trop Dis, 8, 2014, e3230.
91. 91 de Alwis, R, Beltramello, M, Messer, WB, et al. In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection. PLoS Negl Trop Dis, 5, 2011, e1188.
92. 92 Smith, SA, de Alwis, AR, Kose, N, et al. The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein. MBio 4 (2013), e00873–e00913.
93. 93 Tsai, W-Y, Durbin, A, Tsai, J-J, Hsieh, S-C, Whitehead, S, Wang, W-K, Complexity of neutralizing antibodies against multiple dengue virus serotypes after heterotypic immunization and secondary infection revealed by in-depth analysis of cross-reactive antibodies. J Virol 89 (2015), 7348–7362.
94. 94 Fibriansah, G, Tan, JL, Smith, SA, et al. A highly potent human antibody neutralizes dengue virus serotype 3 by binding across three surface proteins. Nat Commun, 6, 2015, 6341.
95. 95 Fibriansah, G, Tan, JL, Smith, SA, et al. A potent anti-dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface. EMBO Mol Med 6 (2014), 358–371.
96. 96 Fibriansah, G, Ibarra, KD, Ng, T, et al. Cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers. Science 349 (2015), 88–91.
97. 97 Teoh, EP, Kukkaro, P, Teo, EW, et al. The structural basis for serotype-specific neutralization of dengue virus by a human antibody. Sci Transl Med, 4, 2012, 139ra83.
98. 98 de Alwis, R, Smith, SA, Olivarez, NP, et al. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci USA 109 (2012), 7439–7444.
99. 99 Messer, WB, Yount, BL, Royal, SR, et al. Functional transplant of a dengue virus serotype 3 (DENV3)-specific human monoclonal antibody epitope into DENV1. J Virol 90 (2016), 5090–5097.
100. 100 Halstead, SB, In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody. J Infect Dis 140 (1979), 527–533.
101. 101 Goncalvez, AP, Engle, RE, St Claire, M, Purcell, RH, Lai, C-J, Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc Natl Acad Sci USA 104 (2007), 9422–9427.
102. 102 Zellweger, RM, Prestwood, TR, Shresta, S, Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease. Cell Host Microbe 7 (2010), 128–139.
103. 103 Williams, KL, Sukupolvi-Petty, S, Beltramello, M, et al. Therapeutic efficacy of antibodies lacking Fcγ receptor binding against lethal dengue virus infection is due to neutralizing potency and blocking of enhancing antibodies [corrected]. PLoS Pathog, 9, 2013, e1003157.
104. 104 Simmons, CP, Chau, TNB, Thuy, TT, et al. Maternal antibody and viral factors in the pathogenesis of dengue virus in infants. J Infect Dis 196 (2007), 416–424.
105. 105 Chau, TNB, Quyen, NTH, Thuy, TT, et al. Dengue in Vietnamese infants—results of infection-enhancement assays correlate with age-related disease epidemiology, and cellular immune responses correlate with disease severity. J Infect Dis 198 (2008), 516–524.
106. 106 Chau, TNB, Hieu, NT, Anders, KL, et al. Dengue virus infections and maternal antibody decay in a prospective birth cohort study of Vietnamese infants. J Infect Dis 200 (2009), 1893–1900.
107. 107 Kliks, SC, Nimmanitya, S, Nisalak, A, Burke, DS, Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am J Trop Med Hyg 38 (1988), 411–419.
108. 108 Clapham, H, Cummings, DAT, Nisalak, A, et al. Epidemiology of infant dengue cases illuminates serotype-specificity in the interaction between immunity and disease, and changes in transmission dynamics. PLoS Negl Trop Dis, 9, 2015, e0004262.
109. 109 Hammond, SN, Balmaseda, A, Pérez, L, et al. Differences in dengue severity in infants, children, and adults in a 3-year hospital-based study in Nicaragua. Am J Trop Med Hyg 73 (2005), 1063–1070.
110. 110 Kliks, SC, Nisalak, A, Brandt, WE, Wahl, L, Burke, DS, Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am J Trop Med Hyg 40 (1989), 444–451.
111. 111 Libraty, DH, Acosta, LP, Tallo, V, et al. A prospective nested case-control study of dengue in infants: rethinking and refining the antibody-dependent enhancement dengue hemorrhagic fever model. PLoS Med, 6, 2009, e1000171.
112. 112 Laoprasopwattana, K, Libraty, DH, Endy, TP, et al. Dengue virus (DV) enhancing antibody activity in preillness plasma does not predict subsequent disease severity or viremia in secondary DV infection. J Infect Dis 192 (2005), 510–519.
113. 113 Halstead, SB, Dengue antibody-dependent enhancement: knowns and unknowns. Microbiol Spectr 2 (2014), 249–271.
114. 114 Bernasconi, NL, Traggiai, E, Lanzavecchia, A, Maintenance of serological memory by polyclonal activation of human memory B cells. Science 298 (2002), 2199–2202.
115. 115 Amanna, IJ, Slifka, MK, Mechanisms that determine plasma cell lifespan and the duration of humoral immunity. Immunol Rev 236 (2010), 125–138.
116. 116 Amanna, IJ, Carlson, NE, Slifka, MK, Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 357 (2007), 1903–1915.
117. 117 Slifka, MK, Vaccine-mediated immunity against dengue and the potential for long-term protection against disease. Front Immunol, 5, 2014, 195.
118. 118 Dejnirattisai, W, Wongwiwat, W, Supasa, S, et al. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nat Immunol, 16, 2015, 785.
119. 119 Purtha, WE, Tedder, TF, Johnson, S, Bhattacharya, D, Diamond, MS, Memory B cells, but not long-lived plasma cells, possess antigen specificities for viral escape mutants. J Exp Med 208 (2011), 2599–2606.
120. 120 Weiskopf, D, Angelo, MA, Bangs, DJ, et al. The human CD8+ T cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes. J Virol 89 (2015), 120–128.
121. 121 Rothman, AL, Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nat Rev Immunol 11 (2011), 532–543.
122. 122 Yauch, LE, Zellweger, RM, Kotturi, MF, et al. A protective role for dengue virus-specific CD8+ T cells. J Immunol 182 (2009), 4865–4873.
123. 123 Hatch, S, Endy, TP, Thomas, S, et al. Intracellular cytokine production by dengue virus-specific T cells correlates with subclinical secondary infection. J Infect Dis 203 (2011), 1282–1291.
124. 124 Weiskopf, D, Angelo, MA, de Azeredo, EL, et al. Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells. Proc Natl Acad Sci USA 110 (2013), E2046–E2053.
125. 125 Weiskopf, D, Cerpas, C, Angelo, MA, et al. Human CD8+ T cell responses against the 4 dengue virus serotypes are associated with distinct patterns of protein targets. J Infect Dis 212 (2015), 1743–1751.
126. 126 Guy, B, Nougarede, N, Begue, S, et al. Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects. Vaccine 26 (2008), 5712–5721.
127. 127 Mangada, MM, Rothman, AL, Altered cytokine responses of dengue-specific CD4+ T cells to heterologous serotypes. J Immunol 175 (2005), 2676–2683.
128. 128 Yauch, LE, Prestwood, TR, May, MM, et al. CD4+ T cells are not required for the induction of dengue virus-specific CD8+ T cell or antibody responses but contribute to protection after vaccination. J Immunol 185 (2010), 5405–5416.
129. 129 Weiskopf, D, Bangs, DJ, Sidney, J, et al. Dengue virus infection elicits highly polarized CX3CR1+ cytotoxic CD4+ T cells associated with protective immunity. Proc Natl Acad Sci USA 112 (2015), E4256–E4263.
130. 130 Pagni, S, Fernandez-Sesma, A, Evasion of the human innate immune system by dengue virus. Immunol Res 54 (2012), 152–159.
131. 131 Popper, SJ, Gordon, A, Liu, M, Balmaseda, A, Harris, E, Relman, DA, Temporal dynamics of the transcriptional response to dengue virus infection in Nicaraguan children. PLoS Negl Trop Dis, 6, 2012, e1966.
132. 132 Simmons, CP, Popper, S, Dolocek, C, et al. Patterns of host genome-wide gene transcript abundance in the peripheral blood of patients with acute dengue hemorrhagic fever. J Infect Dis 195 (2007), 1097–1107.
133. 133 Kwissa, M, Nakaya, HI, Onlamoon, N, et al. Dengue virus infection induces expansion of a CD14+CD16+ monocyte population that stimulates plasmablast differentiation. Cell Host Microbe 16 (2014), 115–127.
134. 134 Koraka, P, Suharti, C, Setiati, TE, et al. Kinetics of dengue virus-specific serum immunoglobulin classes and subclasses correlate with clinical outcome of infection. J Clin Microbiol 39 (2001), 4332–4338.
135. 135 Laoprasopwattana, K, Libraty, DH, Endy, TP, et al. Antibody-dependent cellular cytotoxicity mediated by plasma obtained before secondary dengue virus infections: potential involvement in early control of viral replication. J Infect Dis 195 (2007), 1108–1116.
136. 136 García, G, Arango, M, Pérez, AB, et al. Antibodies from patients with dengue viral infection mediate cellular cytotoxicity. J Clin Virol 37 (2006), 53–57.
137. 137 Avirutnan, P, Punyadee, N, Noisakran, S, et al. Vascular leakage in severe dengue virus infections: a potential role for the nonstructural viral protein NS1 and complement. J Infect Dis 193 (2006), 1078–1088.
138. 138 Markoff, LJ, Innis, BL, Houghten, R, Henchal, LS, Development of cross-reactive antibodies to plasminogen during the immune response to dengue virus infection. J Infect Dis 164 (1991), 294–301.
139. 139 Falconar, AK, The dengue virus nonstructural-1 protein (NS1) generates antibodies to common epitopes on human blood clotting, integrin/adhesin proteins and binds to human endothelial cells: potential implications in haemorrhagic fever pathogenesis. Arch Virol 142 (1997), 897–916.
140. 140 Lin, Y-S, Yeh, T-M, Lin, C-F, et al. Molecular mimicry between virus and host and its implications for dengue disease pathogenesis. Exp Biol Med (Maywood) 236 (2011), 515–523.
141. 141 Chuang, Y-C, Lin, Y-S, Liu, H-S, Yeh, T-M, Molecular mimicry between dengue virus and coagulation factors induces antibodies to inhibit thrombin activity and enhance fibrinolysis. J Virol 88 (2014), 13759–13768.
142. 142 Chuang, Y-C, Lin, Y-S, Liu, H-S, Wang, J-R, Yeh, T-M, Antibodies against thrombin in dengue patients contain both anti-thrombotic and pro-fibrinolytic activities. Thromb Haemost 110 (2013), 358–365.
143. 143 Modhiran, N, Watterson, D, Muller, DA, et al. Dengue virus NS1 protein activates cells via Toll-like receptor 4 and disrupts endothelial cell monolayer integrity. Sci Transl Med, 7, 2015, 304ra142.
144. 144 Beatty, PR, Puerta-Guardo, H, Killingbeck, SS, Glasner, DR, Hopkins, K, Harris, E, Dengue virus NS1 triggers endothelial permeability and vascular leak that is prevented by NS1 vaccination. Sci Transl Med, 7, 2015, 304ra141.
145. 145 Puerta-Guardo, H, Glasner, DR, Harris, E, Dengue Virus NS1 disrupts the endothelial glycocalyx, leading to hyperpermeability. PLoS Pathog, 12, 2016, e1005738.
146. 146 Vannice, KS, Roehrig, JT, Hombach, J, Next generation dengue vaccines: a review of the preclinical development pipeline. Vaccine 33 (2015), 7091–7099.
147. 147 Sampath, S, Carrico, C, Janes, J, et al. Glycan masking of Plasmodium vivax Duffy binding protein for probing protein binding function and vaccine development. PLoS Pathog, 9, 2013, e1003420.
148. 148 McLellan, JS, Correia, BE, Chen, M, et al. Design and characterization of epitope-scaffold immunogens that present the motavizumab epitope from respiratory syncytial virus. J Mol Biol 409 (2011), 853–866.
149. 149 Guy, B, Jackson, N, Dengue vaccine: hypotheses to understand CYD-TDV-induced protection. Nat Rev Microbiol 14 (2015), 45–54.
150. 150 Plotkin, SA, Gilbert, PB, Nomenclature for immune correlates of protection after vaccination. Clin Infect Dis 54 (2012), 1615–1617.